BACKGROUND & AIMS: Although nonalcoholic fatty liver disease (NAFLD) is increasingly common, only a minority of affected individuals develop fibrotic liver disease. Based on its role in liver growth and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD progression. METHODS: KLF6 expression in 31 fibrosis scored NAFLD liver biopsy specimens was assessed by real-time polymerase chain reaction. Transfected minigene constructs were used to study the effect of a polymorphism, KLF6-IVS1-27G>A, that promotes KLF6 alternative splicing in vitro. We genotyped KLF6-IVS1-27G>A in 3 groups of patients (UK group 1, n = 306; Italian group 2, n = 109; trio group 3, n = 61 children and parents). RESULTS: KLF6 expression was increased in association with increased steatosis, inflammation, and fibrosis in NAFLD livers. KLF6-IVS1-27G>A promoted alternative splicing of KLF6 and abrogated the up-regulation of both alpha-smooth muscle actin and collagen 1 in LX-2 cells. Group 1 genotyping identified KLF6-IVS1-27G>A in 44 of 306 (14.4%) patients. Notably, KLF6-IVS1-27G>A was associated significantly with milder NAFLD, with only 25% having more advanced fibrosis compared with 45% of wild-type (wt) individuals. This trend was confirmed in group 2. A linear regression analysis including all 415 patients, adjusted for age, sex, body mass index, and blood glucose level, confirmed that presence of the wt KLF6 allele was an independent predictor of fibrotic NAFLD. Furthermore, we have shown preferential transmission of the wt allele to children with fibrotic NAFLD. CONCLUSIONS: We report a functional polymorphism in the KLF6 gene associated with advanced NAFLD and believe further study of KLF6 may enhance our understanding of this disease process.
BACKGROUND & AIMS: Although nonalcoholic fatty liver disease (NAFLD) is increasingly common, only a minority of affected individuals develop fibrotic liver disease. Based on its role in liver growth and repair, we explored whether Kruppel-like factor 6 (KLF6) plays a role in NAFLD progression. METHODS:KLF6 expression in 31 fibrosis scored NAFLD liver biopsy specimens was assessed by real-time polymerase chain reaction. Transfected minigene constructs were used to study the effect of a polymorphism, KLF6-IVS1-27G>A, that promotes KLF6 alternative splicing in vitro. We genotyped KLF6-IVS1-27G>A in 3 groups of patients (UK group 1, n = 306; Italian group 2, n = 109; trio group 3, n = 61 children and parents). RESULTS:KLF6 expression was increased in association with increased steatosis, inflammation, and fibrosis in NAFLD livers. KLF6-IVS1-27G>A promoted alternative splicing of KLF6 and abrogated the up-regulation of both alpha-smooth muscle actin and collagen 1 in LX-2 cells. Group 1 genotyping identified KLF6-IVS1-27G>A in 44 of 306 (14.4%) patients. Notably, KLF6-IVS1-27G>A was associated significantly with milder NAFLD, with only 25% having more advanced fibrosis compared with 45% of wild-type (wt) individuals. This trend was confirmed in group 2. A linear regression analysis including all 415 patients, adjusted for age, sex, body mass index, and blood glucose level, confirmed that presence of the wt KLF6 allele was an independent predictor of fibrotic NAFLD. Furthermore, we have shown preferential transmission of the wt allele to children with fibrotic NAFLD. CONCLUSIONS: We report a functional polymorphism in the KLF6 gene associated with advanced NAFLD and believe further study of KLF6 may enhance our understanding of this disease process.
Authors: L Xu; A Y Hui; E Albanis; M J Arthur; S M O'Byrne; W S Blaner; P Mukherjee; S L Friedman; F J Eng Journal: Gut Date: 2005-01 Impact factor: 23.059
Authors: Goutham Narla; Analisa DiFeo; Shen Yao; Asoka Banno; Eldad Hod; Helen L Reeves; Rui F Qiao; Olga Camacho-Vanegas; Alice Levine; Alexander Kirschenbaum; Andrew M Chan; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682
Authors: Goutham Narla; Analisa Difeo; Helen L Reeves; Daniel J Schaid; Jennifer Hirshfeld; Eldad Hod; Amanda Katz; William B Isaacs; Scott Hebbring; Akira Komiya; Shannon K McDonnell; Kathleen E Wiley; Steven J Jacobsen; Sarah D Isaacs; Patrick C Walsh; S Lilly Zheng; Bao-Li Chang; Danielle M Friedrichsen; Janet L Stanford; Elaine A Ostrander; Arul M Chinnaiyan; Mark A Rubin; Jianfeng Xu; Stephen N Thibodeau; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: V Ratziu; A Lalazar; L Wong; Q Dang; C Collins; E Shaulian; S Jensen; S L Friedman Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205
Authors: Samer Gawrieh; Miranda C Marion; Richard Komorowski; James Wallace; Michael Charlton; Ahmed Kissebah; Carl D Langefeld; Michael Olivier Journal: Dig Dis Sci Date: 2011-12-09 Impact factor: 3.199
Authors: Bernd Schnabl; Barbara Czech; Daniela Valletta; Thomas S Weiss; Georgi Kirovski; Claus Hellerbrand Journal: Int J Clin Exp Pathol Date: 2011-09-22
Authors: Samer Gawrieh; Tesfaye M Baye; Melanie Carless; James Wallace; Richard Komorowski; David E Kleiner; Deborah Andris; Bassem Makladi; Regina Cole; Michael Charlton; Joanne Curran; Thomas D Dyer; Jac Charlesworth; Russell Wilke; John Blangero; Ahmed H Kissebah; Michael Olivier Journal: Obes Surg Date: 2010-12 Impact factor: 4.129
Authors: Luca Miele; Giovanni Gasbarrini; Valentina Giorgio; Antonio Gasbarrini; Antonio Grieco Journal: Intern Emerg Med Date: 2015-11-24 Impact factor: 3.397
Authors: Joe Gray; Dipankar Chattopadhyay; Gary S Beale; Gillian L Patman; Luca Miele; Barry P King; Stephen Stewart; Mark Hudson; Christopher P Day; Derek M Manas; Helen L Reeves Journal: BMC Cancer Date: 2009-08-05 Impact factor: 4.430